Clinical Trial Update: Phase1/2 Study of IPH6501 in Patients With Relapsed /Refractory B-Cell Non-Hodgkin Lymphoma [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 trial of IPH6501 in relapsed/refractory B-cell non-Hodgkin lymphoma was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-hodgkin Lymphoma

Drugs mentioned

• IPH6501

Snippet

Sponsor: Innate Pharma | Conditions: Non Hodgkin Lymphoma | Phase 1, Phase 2 | Status: TERMINATED